June 17, 2014 – Qu Biologics Inc.
Vancouver, British Columbia – June 17, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced it has appointed Dr. Bob Cory as Vice President, Business Development.
As Vice President, Business Development, Dr. Cory will be responsible for leading Qu’s business and corporate development activities including implementing the company’s’ licensing and strategic partnering strategy and supporting financing and investment initiatives.
Dr. Hal Gunn, CEO of Qu Biologics commented, “Bob Cory brings a wealth of experience in key business development initiatives that have shaped the success of a number of biotechnology companies.” Dr. Gunn added, “Bob is joining Qu at a pivotal stage of growth as our programs mature to a partner-ready stage and as we prepare for multiple clinical trials. We are thrilled to welcome him to our leadership team.”
About Dr. Bob Cory
Dr. Cory has over 15 years of business and corporate development leadership experience in the biopharmaceutical industry. Prior to joining Qu, Dr. Cory was VP and Head of Global Business Development for biOasis Technologies. In addition, Dr. Cory has held executive leadership roles in business and corporate development at Migenix and Illumigen Biosiences. In these roles he was responsible for leading successful collaboration and strategic partnering transactions with a number of multi-national pharmaceutical and biotech companies. Dr. Cory received his Ph.D. in biochemistry from the University of Waterloo and holds an MBA (finance and strategy) from the Laurier School of Business and Economics.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body’s immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company is currently recruiting participants for a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn’s disease.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.